Eliem Therapeutics is developing budoprutug, an anti-CD19 monoclonal antibody that targets and depletes CD19-positive B cells to reduce pathogenic autoantibodies in autoimmune diseases such as systemic lupus erythematosus and immune thrombocytopenia. This approach aims to provide disease-modifying treatment options for patients suffering from these conditions, addressing the underlying mechanisms of inflammation and tissue damage.
Funding
Funding not disclosed
Founders
Product
Problem
Many autoimmune diseases, such as systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), and membranous nephropathy (MN), are driven by pathogenic autoantibodies produced by CD19-positive B cells, leading to inflammation and tissue damage. Current treatments often fail to address the underlying mechanisms of these diseases.
Solution
Climb Bio is developing budoprutug, an anti-CD19 monoclonal antibody, to selectively target and deplete CD19-positive B cells, including antibody-secreting cells. By reducing the population of these B cells, budoprutug aims to directly lower the levels of pathogenic autoantibodies responsible for autoimmune-driven inflammatory diseases. In a Phase 1b clinical trial in membranous nephropathy, budoprutug demonstrated a complete remission of proteinuria in a significant percentage of patients. This approach has the potential to be disease-modifying in autoantibody-mediated diseases like SLE, ITP and MN.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases driven by pathogenic autoantibodies, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, as well as the physicians treating these conditions.
Features
- Anti-CD19 monoclonal antibody designed for targeted depletion of CD19-positive B cells.
- Potential to reduce pathogenic autoantibodies in autoimmune diseases.
- Demonstrated complete remission of proteinuria in a Phase 1b clinical trial for membranous nephropathy.
- Designed to target and deplete CD19-expressing B cells known to produce autoantibodies relevant in SLE.
- May decrease the production of autoantibodies, increase platelet count and ameliorate disease in ITP.